FDA grants priority review for HIF-2α inhibitor belzutifan (MK-6482)

The US Food and Drug Administration (FDA) has granted priority review for a marketing license for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, belzutifan. Belzutifan is a new medicine for the treatment of patients with von Hippel-Lindau (VHL) renal cell carcinoma (RCC) who do not need surgery immediately. Kidney cancers frequently have mutations in a gene called the […]

read more

Updated results from a trial with belzutifan for people with advanced kidney cancer

Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in a number of changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks the action of HIF-2α. In a small […]

read more

HIF-2α inhibitor belzutifan to be fast-tracked for approval for VHL kidney cancer

Kidney cancers frequently have mutations in a gene called the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in a number of changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks […]

read more

ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer

In a small phase 2 study presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), the novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), showed promising anti-cancer activity in combination with cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) that had been previously treated. Kidney cancers develop […]

read more

2020 top stories in kidney cancer

This article summarises the key breakthroughs in the treatment of renal cell carcinoma (RCC) in 2020, including a new first-line VEGF-TKI and immunotherapy combination (cabozantinib plus nivolumab) and immunotherapy as a new standard of treatment for patients with non−clear cell RCC and sarcomatoid RCC. Read more in Practice Update here Watch a video interview on […]

read more

IKCS 2020: Treatment selection in kidney cancer

During this interview, Dr Rana McKay from the University of California in San Diego gives a succinct overview of the 19th Annual Meeting of the International Kidney Cancer Symposium (IKCS 2020), including highlights from the meeting. She also discussed the effects of delaying surgery for patients with low stage (T1 and T2) renal cell carcinoma […]

read more

HIF2α inhibitor provides significant clinical benefit in patients with VHL kidney cancer

One of the major breakthroughs this year the hypoxia-inducible factor (HIF)-2α inhibitor: MK6482 for von Hippel-Lindau (VHL) disease–related clear cell renal cell carcinoma (RCC). VHL disease is a hereditary disease that affects many organs of the body, such as the eyes, brain, spine, pancreas, kidneys and lymphatic system. It is caused by a mutation in […]

read more

Future for VHL kidney cancer is bright

Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always been difficult to treat. However, a group of researchers led by Dr William G. Kaelin Jr from the Dana-Faber Cancer Institute and Harvard Medical School in America have discovered treatments including immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors for the treatment of VHL-associated RCC. He […]

read more

ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer

At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Cristina Suarez from the Hospital Universitari Vall D’Hebron and Vall D’Hebron Institute of Oncology in Barcelona, Spain presented an update of the clinical data from the phase 2 study of oral HIF-2a MK-6482 in Von Hippel-Lindau disease-associated cancers. Von Hippel-Lindau disease is a […]

read more

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]

read more
Showing 1 to 10 of 17 results
  TOP